Skip to content

Advertisement

  • Research
  • Open Access

Simvastatin attenuates tibial bone loss in rats with type 1 diabetes and periodontitis

†Contributed equally
Journal of Translational Medicine201816:306

https://doi.org/10.1186/s12967-018-1681-6

©  The Author(s) 2018

  • Received: 21 August 2018
  • Accepted: 6 November 2018
  • Published:

Abstract

Background

Diabetes induces long bone loss and aggravation of periodontitis-induced alveolar bone loss. Simvastatin (SIM), which is a lipid-lowering agent is known to have an anabolic effect on bone. Therefore, we investigated effect of SIM on tibial and alveolar bone loss in type 1 diabetic rats with periodontitis.

Methods

Rats were divided into control (C), diabetes with periodontitis (DP), and diabetes with periodontitis treated with SIM (DPS) groups. DP and DPS groups were intravenously injected with streptozotocin (50 mg/kg), and C group was injected with citrate buffer. Seven days later (day 0), periodontitis was induced by ligatures of mandibular first molars. DP and DPS groups were orally administered vehicle or SIM (30 mg/kg) from day 0 to days 3, 10, or 20. Alveolar and tibial bone loss was measured using histological and m-CT analysis alone or in combination. Osteoclast number and sclerostin-positive osteocytes in tibiae were evaluated by tartrate-resistant acid phosphatase and immunohistochemical staining, respectively. Glucose, triglyceride (TG), cholesterol (CHO), and low-density lipoprotein (LDL) were evaluated.

Results

Consistent with diabetes induction, the DP group showed higher glucose and TG levels at all timepoints and higher CHO levels on day 20 than C group. Compared to the DP group, the DPS group exhibited reduced levels of glucose (day 3), TG (days 10 and 20), CHO, and LDL levels (day 20). Bone loss analysis revealed that the DP group had lower bone volume fraction, bone mineral density, bone surface density, and trabecular number in tibiae than C group at all timepoints. Interestingly, the DPS group exhibited elevation of these indices at early stages compared to the DP group. The DPS group showed reduction of osteoclasts (day 3) and sclerostin-positive osteocytes (days 3 and 20) compared with the DP group. There was no difference in alveolar bone loss between DP and DPS groups.

Conclusions

These results suggest that SIM attenuates tibial, but not alveolar bone loss in type 1 diabetic rats with periodontitis. Moreover, attenuation of tibial bone loss by SIM may be related to inhibition of osteoclast formation and reduction of sclerostin expression.

Keywords

  • Diabetes
  • Periodontitis
  • Bone loss
  • Sclerostin
  • Simvastatin

Background

Simvastatin (SIM) inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase and subsequently decreases cholesterol synthesis [1]. Thus, SIM is prescribed as an anti-hyperlipidemic agent for reducing cardiovascular disease. In addition, SIM has anti-inflammatory, angiogenic, and bone anabolic actions, which have generated interest in clinical fields related to inflammatory, ischemic, and bone diseases [2–4].

Periodontitis is an inflammatory disease that induces alveolar bone loss. In periodontitis animal models, SIM treatment has a beneficial effect on alveolar bone level [5–8]. Additionally, SIM treatment resulted in improved radiographic defect depth in periodontitis patients [1, 9, 10]. The prevalence or severity of periodontitis is affected by systemic conditions including menopause, medication, smoking, and metabolic syndrome. SIM treatment prevents alveolar bone loss in ovariectomized rats with periodontitis [11] and recovers cyclosporine A-induced alveolar bone loss in periodontitis rats [12]. In smokers with chronic periodontitis, SIM treatment in combination with nonsurgical treatment improves bone fills [13]. In addition, SIM treatment inhibits lipopolysaccharide (LPS)-induced alveolar bone loss in Zucker fatty rats with increased body weight and high cholesterol level [14].

A complication of diabetes mellitus is bone fractures [15]. As an anabolic agent, SIM is effective in the treatment of facture healing [16]. However, the activity of SIM on bone anabolism under diabetic conditions remains controversial. Bone mineral density (BMD) in SIM-treated subjects with type 2 diabetes mellitus did not show a significant difference compared with untreated subjects with type 2 diabetes mellitus [17]. In contrast, SIM application on calvaria defects was shown to enhance bone defect healing in rats with streptozotocin (STZ)-induced diabetes [18].

Periodontitis is another complication of diabetes mellitus. Diabetic patients with difficulty controlling glucose levels are more likely to suffer from periodontitis compared with those with sufficient diabetes control and healthy subjects [19, 20]. One group reported that local SIM application improved alveolar bone fill in patients with type 2 diabetes and chronic periodontitis when combined with scaling and root planing [21]. Until now, systemic SIM administration in diabetic subject with periodontitis has not been evaluated. As diabetic patients can show hyperlipidemia, aggravated alveolar bone loss due to periodontitis, and long bone loss, it is necessary to evaluate the effect of systemic administration of SIM. Studying the effect of systemic SIM administration on bone loss using a diabetic animal model with periodontitis may have translational utility in the clinical field. Animal models of STZ-induced diabetes display pancreatic β-cell destruction and are commonly used as an experimental approach to the study of human type 1 diabetes; however, extrapolation of findings from these models to humans remains challenging due to potential toxicity in the liver and kidneys [22]. Nevertheless, rats with STZ-induced type 1 diabetes and periodontitis provide a good model for observing coincident tibial and alveolar bone loss. In our previous study, rats with STZ-induced diabetes and periodontitis showed increased alveolar bone loss that was attributed to elevation of bone resorption and inhibition of bone formation after the induction of periodontitis compared with control rats [23]. Based on these observations, we hypothesized that SIM could attenuate bone loss during the progression of type 1 diabetes and periodontitis and determined the effect of systemic SIM treatment on alveolar and tibial bone loss using rats with STZ-induced type 1 diabetes and ligature-induced periodontitis.

Methods

Animal model with diabetes and periodontitis and simvastatin treatment

F344 rats (male, 6 weeks old) were purchased from Shizuoka Laboratory Center (Shizuoka, Japan). To minimize distress, all rats were housed three per a cage in specific pathogen-free conditions on a 12 h light/dark cycle at constant temperature (22 °C) and received standard chow and water ad libitum. After acclimation for 1 week, rats were randomly assigned to three groups: control group (C), diabetes with periodontitis group (DP), or diabetes with periodontitis treated with SIM group (DPS). After fasting for 18 h, DP and DPS groups were intravenously injected with STZ (50 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) dissolved in 0.1 M citrate buffer. The C group was injected with citrate buffer alone. Seven days after injection (day 0), blood glucose levels were measured from the tail vein using a glucometer (Accu-Check active system, Roche, Mannheim, Germany). Rats with fasting blood glucose levels over 300 mg/dl were considered diabetic. On day 0, all rats were intraperitoneally injected with a mixture of zoletil 50 (30 mg/kg; Virbac, Carros, France) and rompun (10 mg/kg; Bayer Korea, Ansan, Korea). Following injection, periodontitis was induced in the DP and DPS groups by ligatures of the mandibular first molars with dental floss to induce biofilm formation. SIM (30 mg/kg/day, Chong Kun Dang Pharm, Seoul, Korea) was given daily via oral gavage to the DPS group, and saline was given to the DP group. The C group was sacrificed on day 0 (n = 6), and DP and DPS groups were sacrificed on days 3 (DP, n = 6; DPS, n = 7), 10 (DP, n = 4; DPS, n = 4), and 20 (DP, n = 7; DPS, n = 9). The experimental protocol is presented in Fig. 1a. The maintenance of diabetes was confirmed by measuring body weight and the fasting glucose level during the experimental period. The animal protocols were approved by the Institutional Animal Care and Use Committee of Yonsei University (Approval Number: 2015-0345).
Fig. 1
Fig. 1

Experimental scheme and the effects of SIM on body weight and fasting glucose level. Rats were divided into three groups: C, DP, and DPS. a Experimental scheme: 7 days after induction of diabetes by STZ (50 mg/kg) injection, periodontitis was induced by ligatures of the mandibular first molars using dental floss (day 0). After placement of the ligatures, the DPS group was orally administered SIM (30 mg/kg) daily for a duration of 3, 10, or 20 days. b Body weight and c fasting glucose level in each group. Data are presented as the mean ± SE. *P < 0.05 compared with the C group. **P < 0.05

Serum biochemistry

Serum was obtained from all rats under fasting conditions at sacrifice. Levels of serum triglyceride (TG), total cholesterol (CHO), and low-density lipoprotein (LDL) were measured using a Konelab prime 30i automated analyzer (Thermo scientific, Waltham, MA, USA).

Histological analysis of alveolar and tibial bones

Mandibles dissected from rats were fixed with 10% neutral-buffered formalin for 24 h and embedded in paraffin after decalcification with 10% ethylenediaminetetraacetic acid (EDTA) for 2 months. Sagittal sectioned mandibles were cut at 4 μm thickness. Sections, including clear dental pulp of the mesial and distal roots of the first molar, were selected and stained with hematoxylin and eosin (H&E). For determination of alveolar bone loss, the distance between the cementoenamel junction (CEJ) and the alveolar bone crest (ABC) was measured in the distal area, and the alveolar bone area was measured in the region of interest (ROI) of the furcation. Then, the alveolar bone area in the ROI was divided by the ROI. The ROI was 0.8 mm downward from the top of the furcation. For the evaluation of alveolar bone formation, the light pink unmineralized osteoid area between the alveolar bone surface and osteoblasts was measured in the ROI, which was 0.5 mm downward from the ABC in the furcation. For the determination of tibial bone loss, tibiae were fixed with 10% neutral-buffered formalin. After 24 h of fixation, left tibiae were decalcified with 10% EDTA for 1 month after which paraffin embedding was performed. The paraffin blocks were sectioned as previously described, and the sections containing the clear proximal epiphyseal growth plate were selected and H&E stained. The ROI for trabecular bone extended 1.0 mm from 1.0 mm below the growth plate toward the diaphysis (excluding the outer cortical shell). The area of remaining trabecular bone in the ROI was measured and then divided by the ROI. An Aperio AT2 Digital Whole Slide scanner (Leica Microsystems Inc., Buffalo Grove, IL, USA) and Aperio ImageScope software (version 12.3.2.2013, Aperio Technologies Inc., Vista, CA, USA) were used for the slide scanning and analysis, respectively.

Micro-computed tomography analysis of tibiae

Right tibiae were scanned using micro-computed tomography (m-CT, Skyscan1076, Kontich, Belgium). The scanning parameters were set at 70 kV and 139 μA with an exposure time of 1475 ms and a resolution of 18 μm. The trabecular bone structures extending 2 mm from 0.7 mm below the epiphyseal growth plate were chosen as the ROI [24], and three-dimensional images of the specimens were reconstructed. Bone volume fraction (BVF), BMD, bone surface density (BSD), and trabecular number (Tb. N) in the ROI were calculated using the NRecon software (Bruker SkyScan, Aartselaar, Belgium).

Tartrate-resistant acid phosphatase staining

To identify osteoclast formation in tibiae sections, tartrate-resistant acid phosphatase (TRAP) staining was performed using a TRAP stain kit (Wako chemicals, Osaka, Japan). Methyl green (Trevigen, Gaithersburg, MD, USA) was used for the counterstaining, and slides were scanned as described above. The number of TRAP-positive cells in the ROI were counted along the trabecular bone surface, divided by the bone length, and then divided by the percentage of bone area remaining in the ROI. The ROI was area extended 1.0 mm from 1.0 mm below the growth plate toward the diaphysis (excluding the outer cortical shell).

Immunohistochemistry staining

To assess sclerostin expression in tibiae, tibiae sections were deparaffinized in xylene and rehydrated through ethanol series. Sections were incubated with Trypsin Enzymatic Antigen Retrieval Solution (Abcam, Cambridge, UK) for 15 min at 37 °C followed by immersion in 3% H2O2 in methanol for 20 min to block endogenous peroxidase. After blocking in normal horse serum (Vector Laboratories, Burlingame, CA, USA) for 20 min, the sections were incubated overnight at 4 °C with goat anti-sclerostin antibody (1:50 dilution, R&D Systems, Minneapolis, MN, USA). After incubation with anti-goat secondary antibody (Vector Laboratories) for 20 min, sections were developed with 3,3-diaminobenzidine tetrahydrochloride substrate chromogen system (DAKO, Botany, Australia) and counterstained with methyl green. Slides were scanned as described above. The number of sclerostin-positive osteocytes in the ROI was divided by the number of total osteocytes in the ROI. The ROI was the same as the ROI for osteoclast counting.

Statistical analysis

All statistical comparisons were made using a statistical analysis program (SPSS, Chicago, IL, USA). Significant differences were determined using one-way analysis of variance with Scheffé’s post hoc test. A value of P < 0.05 was considered statistically significant. Data are expressed as the mean ± standard error (SE).

Results

SIM reduces body weight and fasting glucose level at an early stage in diabetic rats with periodontitis

Body weight was reduced and fasting glucose level was elevated in the DP and DPS groups compared with the C group for the duration of the experimental period (Fig. 1b, c). Interestingly, the DPS group had higher body weight and lower fasting glucose level than the DP group on day 3.

Serum TG, CHO, and LDL levels are reduced with SIM treatment

TG level was higher in the DP group than the C group during the experimental period but was lower in the DPS group than the DP group on days 10 and 20 (Fig. 2a). On day 20, CHO level was higher in the DP group than the C group, but was lower in the DPS group than the DP group (Fig. 2b). In terms of LDL, the DPS group also showed lower level than the DP group on day 20 (Fig. 2c).
Fig. 2
Fig. 2

The effects of SIM on serum lipid levels. The serum levels of a TG, b CHO, and c LDL of each group. Data are presented as the mean ± SE. *P < 0.05 compared with the C group. **P < 0.05. (C, n = 6; day 3: DP, n = 6 and DPS, n = 7; day 10: DP, n = 4 and DPS, n = 4; day 20: DP, n = 7 and DPS, n = 9)

Alveolar bone loss is not attenuated by SIM treatment

The effect of SIM on alveolar bone loss and formation of first molars was estimated by measuring the CEJ- ABC distance in the distal area (Fig. 3a, b), the alveolar bone area in the furcation (Fig. 3a, c), and the osteoid area in the furcation (Fig. 3d). The CEJ-ABC distance was higher in the DP and DPS groups than the C group, and there was no difference between the DP and DPS groups. Alveolar bone area in the DP group was lower than the C group for the duration of the experimental period, and the DPS group was lower on days 10 and 20. However, there was no difference between the DP and DPS groups. Similarly, the osteoid area was lower in the DP and DPS groups than the C group for the entire experimental period, and there was no difference between the DP and DPS groups.
Fig. 3
Fig. 3

The effects of SIM on alveolar bone loss and osteoid area. a ROI and representative images for the measurement of alveolar bone loss (H&E staining). The CEJ-ABC distance in the distal area (upper panels, black arrow) and the alveolar bone area (pale blue color) in the ROI (black line) of the furcation (lower panels) were measured in each rat. b The measurement of the CEJ-ABC distance in the distal area of each group. c Alveolar bone area as a percent of the ROI in the furcation of each group. d Osteoid area in the furcation of each group. Data are presented as the mean ± SE. Scale bar = 100 μm. *P < 0.05 compared with the C group. (C, n = 6; day 3: DP, n = 6 and DPS, n = 7; day 10: DP, n = 4 and DPS, n = 4; day 20: DP, n = 7 and DPS, n = 9)

SIM reduces tibial bone loss

The effect of SIM on tibial bone loss was estimated by m-CT (Fig. 4a) and histological analysis (Fig. 4b). In m-CT analysis, levels of BVF, BMD, BSD, and Tb. N were lower in the DP group than the C group during the experimental period. On day 3, the DPS group showed higher levels of BVF, BSD, and Tb. N than the DP group. Additionally, on day 10, the DPS group showed increased levels of BVF and BMD compared with the DP group. Finally, on day 20, there was no difference between the DPS and DP groups. In histological analysis, tibial bone area in the DP group was lower than that of the C group at all timepoints, but the DPS group was only lower than the C group on day 20. Interestingly, tibial bone area was higher in the DPS group than the DP group for the duration of the experimental period.
Fig. 4
Fig. 4

The effects of SIM on tibial bone loss. a Parameters of m-CT analysis: BVF, BMD, BSD, and Tb. N in each group. (C, n = 5; day 3: DP, n = 5 and DPS, n = 5; day 10: DP, n = 4 and DPS, n = 4; day 20: DP, n = 5 and DPS, n = 6). b Trabecular bone area (pale blue color) in the ROI (black line) of tibiae (left panel, H&E staining, scale bar = 100 μm) and measurement of trabecular bone area in each group (right panel; C, n = 6; day 3: DP, n = 6 and DPS, n = 7; day 10: DP, n = 4 and DPS, n = 4; day 20: DP, n = 7 and DPS, n = 9). Data are presented as the mean ± SE. *P < 0.05 compared with the C group, **P < 0.05

Osteoclast formation and sclerostin expression in tibiae are reduced with SIM treatment

The effect of SIM on osteoclast formation in tibiae was estimated by TRAP staining (Fig. 5a). On day 3, the number of TRAP-positive osteoclasts was higher in the DP group than the C group and was lower in the DPS group than the DP group. There was no difference among the three groups on days 10 and 20. Sclerostin expression in osteocytes was estimated by immunohistochemistry and subsequent quantification of positive cells relative to the total number of osteocytes (Fig. 5b). On days 3 and 10, the proportion of sclerostin-positive osteocytes was higher in the DP group than the C group. Further, sclerostin-positive osteocyte proportions were reduced in the DPS group compared with the DP group on days 3 and 20.
Fig. 5
Fig. 5

The effects of SIM on osteoclast formation and sclerostin expression in tibiae. a The number of TRAP-positive osteoclasts and b percentage of sclerostin-positive osteocytes in each group. Data are presented as the mean ± SE. *P < 0.05 compared with the C group, **P < 0.05. No number; OCs osteoclasts. (C, n = 6; day 3: DP, n = 6 and DPS, n = 7; day 10: DP, n = 4 and DPS, n = 4; day 20: DP, n = 7 and DPS, n = 9)

Discussion

Patients with poorly controlled type 1 diabetes often present with elevated TG, CHO, and LDL levels [25]. Mice with STZ-induced diabetes also show higher levels of glucose, TG, CHO, and LDL compared with normal mice [26]. Consistent with these reports, our study found that STZ-treated rats with periodontitis exhibited high levels of glucose, TG, and CHO as well as severe weight loss, indicating successful induction of diabetes in our model. In the previous study, the lipid-lowering agent, SIM, reduced CHO and LDL in patients with type 1 diabetes [25]. In this study, systemic SIM treatment attenuated weight loss and decreased glucose, TG, CHO, and LDL levels in STZ-treated rats with periodontitis. The beneficial effects of SIM on weight loss and high glucose level appeared transiently at an early stage. However, the anti-hyperlipidemic effects of SIM were more prominent for the duration of administration. These results suggest that systemic SIM treatment had promising effects during the experimental period in type 1 diabetic rats with periodontitis.

Bone loss is determined by bone resorption of osteoclasts and bone formation of osteoblast. Increases in cathepsin K and the ratio of receptor activator of nuclear factor kappa-Β ligand (RANKL) to osteoprotegerin in tibiae were noted in mice with STZ-induced diabetes [24]. Another group also reported that mice with STZ-induced diabetes had elevated expression of osteoclast-specific genes (matrix metallopeptidase-9, carbonic anhydrase II, RANKL) in tibiae than non-diabetic mice [27]. These studies suggest that bone resorption in tibiae increases under type 1 diabetic conditions. In accordance with these reports, we found that the DP group displayed reduced tibial bone volume and area at all timepoints compared with the C group. The DPS group showed higher BVF, BSD, Tb. N, and BMD levels on days 3 and 10 as well as greater tibial bone area on days 3, 10, and 20 compared with the DP group. The number of TRAP-positive osteoclasts in tibiae was higher in the DP group than in the C group and was lower in the DPS groups than in the DP group on day 3. These results suggest that systemic SIM treatment attenuated tibial bone loss and osteoclast formation under type 1 diabetic conditions at the early stage and the effect of SIM may weaken at later stage with severe bone loss.

Osteoblasts play an important role in bone formation through producing bone matrix proteins. In previous studies, SIM treatment improved bone formation by inhibiting osteoblast apoptosis through the transforming growth factor (TGF)/SMAD family member 3 signaling pathway as well as by stimulating osteoblast differentiation through induction of bone morphogenetic protein-2 expression [16]. Diabetes accelerates bone loss via suppression of bone formation. STZ-treated mice show decreased expression of osteoblast-specific genes (runt-related transcription factor 2, TGF-β) compared with non-diabetic mice [27]. Sclerostin is a WNT antagonist secreted by osteocytes that binds to LDL receptor-related protein 5/6 and inhibits osteoblast differentiation [28]. STZ-treated mice showed increased sclerostin levels in serum and matrix embedded cells of the callus after femur fracture [29]. In the present study, the DP group also showed elevated proportions of sclerostin-positive osteocytes compared with the C group. Interestingly, the proportion of sclerostin-positive osteocytes in the DPS group was lower than the DP group, suggesting that SIM may improve bone formation in type 1 diabetes by inhibiting sclerostin expression in osteocytes.

Our previous work showed severe alveolar bone loss and inhibition of alveolar bone formation with elevated sclerostin expression on day 20 in rats with STZ-induced diabetes and periodontitis [23]. Therefore, to monitor the effect of systemic SIM treatment during the time of these changes, the timepoints selected for this study were days 3, 10, and 20. However, we did not observe beneficial effects of SIM treatment on alveolar bone resorption and formation in type 1 diabetic rats with periodontitis. This suggests that systemic SIM administration during 20 days may not have beneficial effects on the severe alveolar bone loss in type 1 diabetes with periodontitis. The effects of systemic SIM treatment have evaluated under various conditions. For example, systemic SIM treatment for 8 weeks reduced the number of osteoclasts in rats with LPS-induced periodontitis [5]. Further, systemic SIM treatment for 4 weeks decreased RANKL and colony stimulating factor 2 expressions in periodontal tissues of obese rats with LPS-induced periodontitis, suggesting an inhibitory effect of SIM on expression of osteoclastogenesis factors in rats with metabolic syndrome [14]. Finally, systemic SIM administration for 2 months prevented alveolar bone loss in ovariectomized rats with periodontitis [11]. The lack of response to systemic SIM treatment in terms of alveolar bone loss in type 1 diabetic rats with periodontitis in the present study may be due to differences in SIM administration time or the systemic disease model accompanied with periodontitis. To clarify the effect of SIM, it will be necessary to study prolonged systemic SIM administration.

Conclusions

In rats with type 1 diabetes and periodontitis, we did not observe significant prevention of periodontitis-induced alveolar bone loss during 20 days of systemic SIM administration. However, SIM attenuated tibial bone loss at early stage with weak bone loss, but not at late stage with sever bone loss. Moreover, SIM decreased the number of osteoclasts and proportion of sclerostin-positive osteocytes in tibiae. Together, our results suggest that the effect of SIM on tibial bone loss may be related to the inhibition of osteoclast formation and sclerostin expression in type 1 diabetic rats with periodontitis. Our results provide useful information for establishing SIM as a therapeutic strategy for systemic diseases with severe alveolar bone loss.

Notes

Abbreviations

SIM: 

simvastatin

LPS: 

lipopolysaccharide

BMD: 

bone mineral density

STZ: 

streptozotocin

C: 

control

DP: 

diabetes with periodontitis

DPS: 

diabetes with periodontitis treated with simvastatin

TG: 

triglyceride

CHO: 

cholesterol

LDL: 

low-density lipoprotein

EDTA: 

ethylenediaminetetraacetic acid

H&E: 

hematoxylin and eosin

CEJ: 

cementoenamel junction

ABC: 

alveolar bone crest

ROI: 

region of interest

m-CT: 

micro-computed tomography

BVF: 

bone volume fraction

BSD: 

bone surface density

Tb. N: 

trabecular number

TRAP: 

tartrate-resistant acid phosphatase

RANKL: 

receptor activator of nuclear factor kappa-B ligand

TGF: 

transforming growth factor

Declarations

Authors’ contributions

ARK participated in the establishment of the animal model and drafted the manuscript. JHK and AK participated in the establishment of the animal model and histological analysis. YS participated in monitoring the serum biochemistry. JHC advised on the study design and helped to draft the manuscript. EJB and YJY designed the study and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

None.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All the data generated or analyzed during this study are included in this published article.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The animal protocols were approved by the Institutional Animal Care and Use Committee of Yonsei University (Approval Number: 2015-0345).

Funding

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2014R1A2A1A11049412).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Oral Biology, Yonsei University College of Dentistry, 134 Sinchon dong, Seodaemun-gu, Seoul, 120-752, Republic of Korea
(2)
Department of Applied Life Science, The Graduate School, Yonsei University, Seoul, Republic of Korea
(3)
BK21 PLUS Project, Yonsei University College of Dentistry, Seoul, Republic of Korea
(4)
Department of Dental Hygiene, Jeonju Kijeon College, Jeonju, Republic of Korea
(5)
DONG-A Pharm, Yongin-si, Gyeonggi-do, Republic of Korea
(6)
Microbiology and Molecular Biology, Key Laboratory of Oral Medicine, Guangzhou Institute of Oral Disease, Stomatology Hospital of Guangzhou Medical University, Guangzhou, China

References

  1. Bertl K, Parllaku A, Pandis N, Buhlin K, Klinge B, Stavropoulos A. The effect of local and systemic statin use as an adjunct to non-surgical and surgical periodontal therapy—a systematic review and meta-analysis. J Dent. 2017;67:18–28.View ArticleGoogle Scholar
  2. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004–10.View ArticleGoogle Scholar
  3. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946–9.View ArticleGoogle Scholar
  4. Tulbah AS, Ong HX, Colombo P, Young PM, Traini D. Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons. Expert Opin Drug Deliv. 2016;13:1407–20.View ArticleGoogle Scholar
  5. Jin J, Zhang X, Lu Z, Li Y, Lopes-Virella MF, Yu H, Haycraft CJ, Li Q, Kirkwood KL, Huang Y. Simvastatin inhibits lipopolysaccharide-induced osteoclastogenesis and reduces alveolar bone loss in experimental periodontal disease. J Periodontal Res. 2014;49:518–26.View ArticleGoogle Scholar
  6. Bradley AD, Zhang Y, Jia Z, Zhao G, Wang X, Pranke L, Schmid MJ, Wang D, Reinhardt RA. Effect of simvastatin prodrug on experimental periodontitis. J Periodontol. 2016;87:577–82.View ArticleGoogle Scholar
  7. Dalcico R, de Menezes AM, Deocleciano OB, Oria RB, Vale ML, Ribeiro RA, Brito GA. Protective mechanisms of simvastatin in experimental periodontal disease. J Periodontol. 2013;84:1145–57.View ArticleGoogle Scholar
  8. Bertl K, Steiner I, Pandis N, Buhlin K, Klinge B, Stavropoulos A. Statins in nonsurgical and surgical periodontal therapy. A systematic review and meta-analysis of preclinical in vivo trials. J Periodontal Res. 2018;53:267–87.View ArticleGoogle Scholar
  9. Pradeep AR, Thorat MS. Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial. J Periodontol. 2010;81:214–22.View ArticleGoogle Scholar
  10. Pradeep AR, Priyanka N, Kalra N, Naik SB, Singh SP, Martande S. Clinical efficacy of subgingivally delivered 1.2-mg simvastatin in the treatment of individuals with class II furcation defects: a randomized controlled clinical trial. J Periodontol. 2012;83:1472–9.View ArticleGoogle Scholar
  11. Xu XC, Chen H, Zhang X, Zhai ZJ, Liu XQ, Qin A, Lu EY. Simvastatin prevents alveolar bone loss in an experimental rat model of periodontitis after ovariectomy. J Transl Med. 2014;12:284.View ArticleGoogle Scholar
  12. Nassar PO, Nassar CA, Guimaraes MR, Aquino SG, Andia DC, Muscara MN, Spolidorio DM, Rossa C Jr, Spolidorio LC. Simvastatin therapy in cyclosporine A-induced alveolar bone loss in rats. J Periodontal Res. 2009;44:479–88.View ArticleGoogle Scholar
  13. Rao NS, Pradeep AR, Bajaj P, Kumari M, Naik SB. Simvastatin local drug delivery in smokers with chronic periodontitis: a randomized controlled clinical trial. Aust Dent J. 2013;58:156–62.View ArticleGoogle Scholar
  14. Jin J, Machado ER, Yu H, Zhang X, Lu Z, Li Y, Lopes-Virella MF, Kirkwood KL, Huang Y. Simvastatin inhibits LPS-induced alveolar bone loss during metabolic syndrome. J Dent Res. 2014;93:294–9.View ArticleGoogle Scholar
  15. Valderrabano RJ, Linares MI. Diabetes mellitus and bone health: epidemiology, etiology and implications for fracture risk stratification. Clin Diabetes Endocrinol. 2018;4:9.View ArticleGoogle Scholar
  16. Moshiri A, Sharifi AM, Oryan A. Role of simvastatin on fracture healing and osteoporosis: a systematic review on in vivo investigations. Clin Exp Pharmacol Physiol. 2016;43:659–84.View ArticleGoogle Scholar
  17. Uysal AR, Delibasi T, Erdogan MF, Kamel N, Baskal N, Tonyukuk V, Corapcioglu D, Gullu S, Erdogan G. Effect of simvastatin use on bone mineral density in women with type 2 diabetes. Endocr Pract. 2007;13:114–6.View ArticleGoogle Scholar
  18. Ezirganli S, Kazancioglu HO, Mihmanli A, Aydin MS, Sharifov R, Alkan A. The effect of local simvastatin application on critical size defects in the diabetic rats. Clin Oral Implants Res. 2014;25:969–76.View ArticleGoogle Scholar
  19. Polak D, Shapira L. An update on the evidence for pathogenic mechanisms that may link periodontitis and diabetes. J Clin Periodontol. 2018;45:150–66.View ArticleGoogle Scholar
  20. Jindal A, Parihar AS, Sood M, Singh P, Singh N. Relationship between severity of periodontal disease and control of diabetes (glycated hemoglobin) in patients with type 1 diabetes mellitus. J Int Oral Health. 2015;7:17–20.PubMedPubMed CentralGoogle Scholar
  21. Pradeep AR, Rao NS, Bajaj P, Kumari M. Efficacy of subgingivally delivered simvastatin in the treatment of patients with type 2 diabetes and chronic periodontitis: a randomized double-masked controlled clinical trial. J Periodontol. 2013;84:24–31.View ArticleGoogle Scholar
  22. Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2015;70:5–47.PubMedGoogle Scholar
  23. Kim JH, Lee DE, Woo GH, Cha JH, Bak EJ, Yoo YJ. Osteocytic sclerostin expression in alveolar bone in rats with diabetes mellitus and ligature-induced periodontitis. J Periodontol. 2015;86:1005–11.View ArticleGoogle Scholar
  24. Motyl K, McCabe LR. Streptozotocin, type I diabetes severity and bone. Biol Proced Online. 2009;11:296–315.View ArticleGoogle Scholar
  25. Kjaer K, Hangaard J, Petersen NE, Hagen C. Effect of simvastatin in patients with type I (insulin-dependent) diabetes mellitus and hypercholesterolemia. Acta Endocrinol. 1992;126:229–32.View ArticleGoogle Scholar
  26. Zhang Y, Wu L, Ma Z, Cheng J, Liu J. Anti-diabetic, anti-oxidant and anti-hyperlipidemic activities of flavonoids from corn silk on STZ-Induced diabetic mice. Molecules. 2015;21:E7.View ArticleGoogle Scholar
  27. Yu SG, Zhang CJ, Xu XE, Sun JH, Zhang L, Yu PF. Ursolic acid derivative ameliorates streptozotocin-induced diabestic bone deleterious effects in mice. Int J Clin Exp Pathol. 2015;8:3681–90.PubMedPubMed CentralGoogle Scholar
  28. ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008;90(Suppl 1):31–5.View ArticleGoogle Scholar
  29. Yee CS, Xie L, Hatsell S, Hum N, Murugesh D, Economides AN, Loots GG, Collette NM. Sclerostin antibody treatment improves fracture outcomes in a type I diabetic mouse model. Bone. 2016;82:122–34.View ArticleGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement

Journal of Translational Medicine

ISSN: 1479-5876

Contact us